Skip to content
OpenCapital
Get started

Viking Therapeutics VKTX Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Pfizer logo
PfizerPFE
——
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
——
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
——
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——
Arcus Biosciences logo
Arcus BiosciencesRCUS
——

Other financials

Income statement

See full
Revenue-—
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4.04B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0×0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's available for sale securities debt securities current?
Viking Therapeutics (VKTX) reported available for sale securities debt securities current of $484.85M in Q1 2026.
How has Viking Therapeutics's available for sale securities debt securities current changed year-over-year?
Viking Therapeutics's available for sale securities debt securities current decreased by 40.4% year-over-year, from $813.92M to $484.85M.
What is the long-term trend for Viking Therapeutics's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Viking Therapeutics's available for sale securities debt securities current has grown at a 19.7% compound annual growth rate (CAGR), from $219.27M to $539.93M.